Concord Biotech share price
NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,270.70.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12,860 Cr496th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 46.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 15.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 96,70653.4% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 31 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹257 Crdown 21.03%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹58 Crdown 34.78%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 22.4%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 29 May | Jun 2026Filed 31 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Net profit | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 30.9% | 31.1% | 32.7% | 21.6% | 25.5% | 22.9% | 27.1% | 22.4% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 27% of 596 trading days since May 2024.
At or below today's level on 5% of 724 trading days since Nov 2023.
At or below today's level on 24% of 596 trading days since May 2024.
At or below today's level on 68% of 694 trading days over the last 3 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −38.7% | −30.2% | −13.1% | 0.7% |
Mutual funds holding it
58 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 43 of the 45 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- AddedAdded. Funds that held more shares than at the end of the month before.
- 17
- CutCut. Funds that held fewer shares than at the end of the month before.
- 28
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 2
| Fund | |||
|---|---|---|---|
 DSP Small Cap FundDSP Mutual Fund | 26,19,839 | 1.68% | ₹359.9 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 9,60,000 | 2.25% | ₹131.9 Cr |
| DSP Healthcare FundDSP Mutual Fund | 7,35,820 | 2.70% | ₹101.1 Cr |
 Edelweiss Small Cap FundEdelweiss Mutual Fund | 5,64,819 | 1.11% | ₹77.6 Cr |
 Helios Mid Cap FundHelios Mutual Fund | 1,35,043 | 0.79% | ₹18.5 Cr |
| SBI Balanced Hybrid FundSBI Mutual Fund | 1,20,000 | 0.83% | ₹16.5 Cr |
 ITI Flexi Cap FundITI Mutual Fund | 1,17,004 | 1.01% | ₹16.1 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 1,11,738 | 0.17% | ₹15.3 Cr |
| Helios Small Cap FundHelios Mutual Fund | 1,04,509 | 0.76% | ₹14.4 Cr |
 Baroda BNP Paribas Innovation FundBaroda BNP Paribas Mutual Fund | 80,000 | 1.28% | ₹11.0 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Concord Biotech in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
 Jubilant PharmovaJUBLPHARMA | 14,945 | 42.4 | 2.1 | 13.9 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
 Marksans PharmaMARKSANS | 13,001 | 25.2 | 4.3 | 16.9 | – | – | 17.1% | 19.9% | 0.31% |
 CORONA RemediesCORONA | 12,545 | 63.0 | 16.8 | 39.9 | – | – | 26.6% | 30.9% | 0.49% |
 Akums Drugs and PharmaceuticalsAKUMS | 10,530 | 36.1 | 3.2 | 15.7 | +9.2% | −14.6% | 9.2% | 12.0% | 0.45% |
 Strides Pharma ScienceSTAR | 9,354 | 15.2 | 3.0 | 11.5 | +7.3% | – | 21.7% | 15.1% | 0.49% |
 Viyash ScientificVIYASH | 9,017 | – | 3.1 | 15.5 | +96.5% | – | – | 11.2% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹7.55 |
| 3 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹10.70 |
| 21 Jun 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹8.75 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
23 Oct · Analysts
Sep 2026
24 Sep · Meeting
19 Sep · Board meeting
Concord Biotech share price by year
Each calendar year to 2025.Concord Biotech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,345.60 | −39.1% | 2,345.60 | 1,329.00 |
| 2024 | 2,210.75 | +50.2% | 2,601.10 | 1,366.65 |
| 2023 | 1,471.80 | – | 1,506.10 | 942.80 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,270.50 | 1,279.70 | 1,212.50 | 1,229.30 | 1,228.68 | 96,706 | 53.4% |
| 22 Oct 2026 | 1,270.00 | 1,308.90 | 1,252.90 | 1,270.70 | 1,276.28 | 93,347 | 39.0% |
| 21 Oct 2026 | 1,266.80 | 1,284.00 | 1,251.00 | 1,270.00 | 1,263.95 | 83,316 | 49.6% |
| 19 Oct 2026 | 1,350.00 | 1,350.00 | 1,276.10 | 1,285.80 | 1,301.25 | 79,842 | 56.9% |
| 16 Oct 2026 | 1,362.90 | 1,366.80 | 1,332.00 | 1,339.00 | 1,342.77 | 45,381 | 55.4% |
| 15 Oct 2026 | 1,390.80 | 1,394.90 | 1,350.00 | 1,353.30 | 1,361.04 | 35,984 | 45.7% |
| 14 Oct 2026 | 1,378.80 | 1,395.60 | 1,372.10 | 1,382.10 | 1,384.17 | 63,724 | 57.0% |
| 13 Oct 2026 | 1,355.40 | 1,375.00 | 1,335.50 | 1,369.70 | 1,356.48 | 67,678 | 49.1% |
| 12 Oct 2026 | 1,368.20 | 1,388.60 | 1,350.00 | 1,354.40 | 1,369.14 | 53,163 | 53.2% |
| 9 Oct 2026 | 1,336.00 | 1,370.00 | 1,326.00 | 1,361.40 | 1,351.76 | 1,28,354 | 43.1% |
About Concord Biotech
Concord Biotech Limited develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations, and contract development and manufacturing services (CDMO). It serves more than 300 customers in over 70 countries. Its CDMO and contract research services support pharmaceutical innovators and generic manufacturers. Its products cover immunosuppressants, oncology, anti-bacterial and anti-fungal therapies.
The business has two main lines. The API portfolio has more than 30 fermentation-based products. The formulations line covers oral solid dosage products and injectable medicines made at its Valthera facility. Formulations are sold largely in India through government and corporate hospitals and distribution networks. In the US and in emerging markets in Asia, Africa and Latin America, the company sells through distributors.
The registered office and a plant are at Trasad Road, Dholka, in Ahmedabad district. Unit I at Dholka is the API facility, Unit II is a formulation facility, and Unit IV at Valthera makes injectables. Its facilities have been inspected by regulators including the USFDA, EU GMP and PMDA (Japan). A team of 180 scientists works on research and development.
It was incorporated in 1984. It has a wholly owned subsidiary, Concord Lifegen Limited, set up to strengthen marketing, sales and distribution. It also holds a 75% stake in Stellon Biotech Inc., a United States subsidiary that markets and distributes its products.
Sudhir Vaid, the Chairman and Managing Director, and his son Ankur Vaid, the Joint Managing Director and Chief Executive Officer, are the company's promoters. A promoter is the person or group that set up a company or controls it.
- Legal name
- Concord Biotech Limited
- NSE symbol
- CONCORDBIO
- BSE code
- 543960
- ISIN
- INE338H01029
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 2023
- Face value
- ₹1
- CIN
- L24230GJ1984PLC007440
- Corporate identity number, the registrar of companies' code for it